{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:45Z","timestamp":1790848485126,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T00:00:00Z","timestamp":1578182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012834","name":"Gifu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008467","name":"Fukushima University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2020.01.004","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T01:12:25Z","timestamp":1578532345000},"page":"629-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of 5\u00a0mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study"],"prefix":"10.1016","volume":"156","author":[{"given":"Hirotoshi","family":"Iihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Hayasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senri","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiru","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-3418","authenticated-orcid":false,"given":"Kazuto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6474-9796","authenticated-orcid":false,"given":"Nobuhiro","family":"Kado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Shimaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichirou","family":"Morishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.01.004_bb0005","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. 1.2019 Version. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0010","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. 4.2019 Version. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0015","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. 3.2019 Version. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0025","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0030","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"ESMO Guidelines Committee, Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0035","doi-asserted-by":"crossref","first-page":"vi33","DOI":"10.1093\/annonc\/mdt353","article-title":"Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Colombo","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0040","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JGO.2016.003954","article-title":"Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline","volume":"2","author":"Chuang","year":"2016","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0050","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0055","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0060","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis. 1.2019 Version. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0065","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.01.004_bb0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"Yahata","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0080","first-page":"24","article-title":"Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting","volume":"5","author":"Brafford","year":"2014","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0090","first-page":"675","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2020.01.004_bb0095","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jjco\/hyx084","article-title":"A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy","volume":"47","author":"Nakashima","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10\u00a0mg or 5\u00a0mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0105","first-page":"1285","article-title":"A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study","volume":"15","author":"Navari","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2020.01.004_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0130","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0135","volume":"37","author":"Hashimoto","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0140","article-title":"A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan","author":"Iihara","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.01.004_bb0145","first-page":"5955","article-title":"Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research","volume":"37","author":"Gadducci","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0150","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0155","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","article-title":"Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary","volume":"21","author":"Takeuchi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.004_bb0165","article-title":"Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients","volume":"9","author":"Iihara","year":"2019","journal-title":"BMJ Open"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:03Z","timestamp":1758772323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825820300044"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of 5\u00a0mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}